Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948023810> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2948023810 endingPage "1003" @default.
- W2948023810 startingPage "1003" @default.
- W2948023810 abstract "1003 Background: IMpassion130 evaluated atezo (anti–PD-L1) + nP vs placebo + nP in 1L mTNBC. The primary PFS analysis found that atezo + nP significantly improved PFS in intent-to-treat (ITT) and PD-L1+ pts vs placebo + nP, with efficacy driven by the PD-L1+ population. At that time, the 1st interim OS analysis was conducted (Schmid, NEJM 2018). Here we report the 2nd interim OS analysis. Methods: Eligible pts had histologically documented locally advanced or mTNBC, ECOG PS 0-1 and tumor tissue for PD-L1 testing. Pts were randomized 1:1 to IV atezo 840 mg or placebo on d1 and d15 + nP 100 mg/m 2 on d1, d8 and d15 of each 28-d cycle until progression (stratification factors: prior taxanes, liver metastases, PD-L1 on tumor-infiltrating immune cells [IC]). RECIST 1.1 PFS (in ITT and PD-L1+ pts) and OS (tested in ITT and, if significant, PD-L1+ pts) were co-primary endpoints. Results: OS data are shown (Table). As of data cutoff (Jan 2, 2019), 9% of pts in the atezo + nP arm and 3% in the placebo + nP arm were still on treatment. Statistical significance was not demonstrated in ITT pts, but a 7.0-month improvement in median OS was observed in PD-L1+ pts with atezo + nP (25.0 mo) vs placebo + nP (18.0 mo; HR, 0.71 [95% CI: 0.54, 0.93]). A 4.5-mo safety update (Schneeweiss, ASCO 2019, submitted) showed that atezo + nP remained tolerable. Conclusions: The 2nd IMpassion130 interim OS analysis was consistent with the 1st analysis, confirming clinically meaningful OS benefit with atezo + nP in previously untreated PD-L1+ mTNBC. Clinical trial information: NCT02425891. [Table: see text]" @default.
- W2948023810 created "2019-06-07" @default.
- W2948023810 creator A5003921604 @default.
- W2948023810 creator A5008549101 @default.
- W2948023810 creator A5010278367 @default.
- W2948023810 creator A5012487596 @default.
- W2948023810 creator A5027877389 @default.
- W2948023810 creator A5035762260 @default.
- W2948023810 creator A5041218801 @default.
- W2948023810 creator A5056037326 @default.
- W2948023810 creator A5056565799 @default.
- W2948023810 creator A5060906081 @default.
- W2948023810 creator A5070245248 @default.
- W2948023810 creator A5089392438 @default.
- W2948023810 creator A5089861374 @default.
- W2948023810 creator A5090188675 @default.
- W2948023810 date "2019-05-20" @default.
- W2948023810 modified "2023-10-01" @default.
- W2948023810 title "IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + <i>nab-</i>paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)." @default.
- W2948023810 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.1003" @default.
- W2948023810 hasPublicationYear "2019" @default.
- W2948023810 type Work @default.
- W2948023810 sameAs 2948023810 @default.
- W2948023810 citedByCount "52" @default.
- W2948023810 countsByYear W29480238102019 @default.
- W2948023810 countsByYear W29480238102020 @default.
- W2948023810 countsByYear W29480238102021 @default.
- W2948023810 countsByYear W29480238102022 @default.
- W2948023810 countsByYear W29480238102023 @default.
- W2948023810 crossrefType "journal-article" @default.
- W2948023810 hasAuthorship W2948023810A5003921604 @default.
- W2948023810 hasAuthorship W2948023810A5008549101 @default.
- W2948023810 hasAuthorship W2948023810A5010278367 @default.
- W2948023810 hasAuthorship W2948023810A5012487596 @default.
- W2948023810 hasAuthorship W2948023810A5027877389 @default.
- W2948023810 hasAuthorship W2948023810A5035762260 @default.
- W2948023810 hasAuthorship W2948023810A5041218801 @default.
- W2948023810 hasAuthorship W2948023810A5056037326 @default.
- W2948023810 hasAuthorship W2948023810A5056565799 @default.
- W2948023810 hasAuthorship W2948023810A5060906081 @default.
- W2948023810 hasAuthorship W2948023810A5070245248 @default.
- W2948023810 hasAuthorship W2948023810A5089392438 @default.
- W2948023810 hasAuthorship W2948023810A5089861374 @default.
- W2948023810 hasAuthorship W2948023810A5090188675 @default.
- W2948023810 hasConcept C121608353 @default.
- W2948023810 hasConcept C126322002 @default.
- W2948023810 hasConcept C142724271 @default.
- W2948023810 hasConcept C143998085 @default.
- W2948023810 hasConcept C168563851 @default.
- W2948023810 hasConcept C204787440 @default.
- W2948023810 hasConcept C27081682 @default.
- W2948023810 hasConcept C2775949291 @default.
- W2948023810 hasConcept C2776694085 @default.
- W2948023810 hasConcept C2777292972 @default.
- W2948023810 hasConcept C2777701055 @default.
- W2948023810 hasConcept C2780057760 @default.
- W2948023810 hasConcept C2908647359 @default.
- W2948023810 hasConcept C61943457 @default.
- W2948023810 hasConcept C71924100 @default.
- W2948023810 hasConcept C90924648 @default.
- W2948023810 hasConcept C99454951 @default.
- W2948023810 hasConceptScore W2948023810C121608353 @default.
- W2948023810 hasConceptScore W2948023810C126322002 @default.
- W2948023810 hasConceptScore W2948023810C142724271 @default.
- W2948023810 hasConceptScore W2948023810C143998085 @default.
- W2948023810 hasConceptScore W2948023810C168563851 @default.
- W2948023810 hasConceptScore W2948023810C204787440 @default.
- W2948023810 hasConceptScore W2948023810C27081682 @default.
- W2948023810 hasConceptScore W2948023810C2775949291 @default.
- W2948023810 hasConceptScore W2948023810C2776694085 @default.
- W2948023810 hasConceptScore W2948023810C2777292972 @default.
- W2948023810 hasConceptScore W2948023810C2777701055 @default.
- W2948023810 hasConceptScore W2948023810C2780057760 @default.
- W2948023810 hasConceptScore W2948023810C2908647359 @default.
- W2948023810 hasConceptScore W2948023810C61943457 @default.
- W2948023810 hasConceptScore W2948023810C71924100 @default.
- W2948023810 hasConceptScore W2948023810C90924648 @default.
- W2948023810 hasConceptScore W2948023810C99454951 @default.
- W2948023810 hasIssue "15_suppl" @default.
- W2948023810 hasLocation W29480238101 @default.
- W2948023810 hasOpenAccess W2948023810 @default.
- W2948023810 hasPrimaryLocation W29480238101 @default.
- W2948023810 hasRelatedWork W2034238172 @default.
- W2948023810 hasRelatedWork W2606133764 @default.
- W2948023810 hasRelatedWork W2892354658 @default.
- W2948023810 hasRelatedWork W2921101639 @default.
- W2948023810 hasRelatedWork W2962238349 @default.
- W2948023810 hasRelatedWork W3150004775 @default.
- W2948023810 hasRelatedWork W4235522950 @default.
- W2948023810 hasRelatedWork W4244644787 @default.
- W2948023810 hasRelatedWork W4308252516 @default.
- W2948023810 hasRelatedWork W4322775344 @default.
- W2948023810 hasVolume "37" @default.
- W2948023810 isParatext "false" @default.
- W2948023810 isRetracted "false" @default.
- W2948023810 magId "2948023810" @default.
- W2948023810 workType "article" @default.